Petrelintide
vs Cagrilintide.
Compare petrelintide and cagrilintide by amylin mechanism, Phase 2 and Phase 3 evidence, tolerability records, development stage, and approval status.
What is the difference?
Petrelintide and cagrilintide are separate investigational long-acting amylin analogues being developed as once-weekly injections for weight management. No head-to-head trial has compared them. Petrelintide has a completed Phase 2 ZUPREME-1 result and a sponsor plan to enter Phase 3 in the second half of 2026. Cagrilintide has a monotherapy arm in Phase 3 REDEFINE 1 and an active standalone RENEW Phase 3 program. Their headline weight-loss percentages came from different trials, durations, populations, estimands, escalation plans, and placebo groups. Neither molecule is FDA approved, and the available records do not establish which is more effective, safer, or more tolerable for an individual.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Petrelintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 9 matched NCT records
- Sponsor
- Zealand Pharma + Roche
Cagrilintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 52 matched NCT records
- Sponsor
- Novo Nordisk
Petrelintide vs Cagrilintide: how direct is the evidence?
No participant in the cited sources was randomized between Petrelintide and Cagrilintide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Petrelintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 planned; Phase 2 program active
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialCagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 2
- Results posted
- 0
- Recruiting site observations
- 4
matched NCT records
- Recruiting
- 10
- Results posted
- 2
- Recruiting site observations
- 170
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Petrelintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 planned; Phase 2 program active
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT06662539 · NCT06926842 · NCT07589686
Cagrilintide
Long-acting amylin analogue
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 monotherapy program
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT03856047 · NCT05567796 · NCT07220642 · NCT07220759
Compare the field, then read the limit.
Both names sit in the long-acting amylin category and are increasingly presented as direct alternatives in search results. That similarity makes it easy to rank a 42-week petrelintide result against a 68-week cagrilintide result or to transfer CagriSema evidence to cagrilintide alone. A useful comparison must keep the molecules, monotherapy trials, combination programs, analysis methods, event rates, and development stages separate.
| Field | Petrelintide | Cagrilintide | How to interpret it |
|---|---|---|---|
| Drug design | Long-acting human amylin analogue | Long-acting amylin analogue | Both programs use amylin biology, but a shared class and weekly route do not make the molecules or evidence interchangeable. |
| Monotherapy evidence anchor | Up to 10.7% at 42 weeks in Phase 2 ZUPREME-1 | 11.8% at 68 weeks in the REDEFINE 1 monotherapy arm | Different durations, designs, dose strategies, estimands, and placebo responses prevent a direct percentage ranking. |
| Development stage | Phase 3 initiation planned for the second half of 2026 | Standalone RENEW Phase 3 program active | A sponsor plan to start Phase 3 is not the same milestone as an active pivotal study, and neither status is approval. |
| Combination context | Combination development with Roche incretin assets is planned | Also studied with semaglutide as the separate CagriSema combination | Combination results belong to the exact combined intervention and must not be assigned to either amylin monotherapy. |
| Current status | Investigational and not FDA approved | Investigational and not FDA approved | Neither name identifies an approved retail product, prescribing instruction, pharmacy price, or verified online supply route. |
Why the headline numbers do not name a winner.
ZUPREME-1 reported petrelintide dose-group mean losses of 8.7% to 10.7% at week 42 under the efficacy estimand versus 1.7% with pooled placebo. The cagrilintide monotherapy arm in REDEFINE 1 reported 11.8% at week 68 under the trial-product estimand versus 2.3% with placebo. Those figures can orient readers to each program, but they are not randomized against each other. Cagrilintide's result as part of CagriSema is a different intervention and cannot be credited to cagrilintide monotherapy.
Keep the comparison honest.
- 01
Keep every percentage attached to its exact trial, week, dose strategy, population, estimand, and placebo response.
- 02
Read event-specific tolerability rates inside each study rather than turning a sponsor summary into a cross-trial safety winner.
- 03
Do not transfer CagriSema results to cagrilintide alone or treat a seller-labelled vial as sponsor clinical material.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →